GeoVax Labs (NASDAQ:GOVX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $8.00 price target on the stock.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $3.31 on Tuesday. GeoVax Labs has a one year low of $1.09 and a one year high of $10.24. The company’s fifty day moving average is $1.82 and its two-hundred day moving average is $2.69.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($2.47) EPS for the quarter. On average, equities analysts predict that GeoVax Labs will post -7.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs as of its most recent SEC filing. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.